Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

Burning Rock Biotech (BNR) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Burning Rock Biotech (BNR) over the last 7 years, with Sep 2025 value amounting to -7.88%.

  • Burning Rock Biotech's EBITDA Margin fell 1058.00% to -7.88% in Q3 2025 from the same period last year, while for Sep 2025 it was -14.94%, marking a year-over-year increase of 4088.00%. This contributed to the annual value of -66.53% for FY2024, which is 5432.00% up from last year.
  • Per Burning Rock Biotech's latest filing, its EBITDA Margin stood at -7.88% for Q3 2025, which was up 4.16% from -8.22% recorded in Q2 2025.
  • Burning Rock Biotech's EBITDA Margin's 5-year high stood at 2.70% during Q3 2024, with a 5-year trough of -195.13% in Q1 2022.
  • Over the past 3 years, Burning Rock Biotech's median EBITDA Margin value was -79.02% (recorded in 2024), while the average stood at -66.89%.
  • Per our database at Business Quant, Burning Rock Biotech's EBITDA Margin crashed by 11,843bps in 2021 and then soared by 14,140bps in 2024.
  • Over the past 5 years, Burning Rock Biotech's EBITDA Margin (Quarterly) stood at -186.42% in 2021, then soared by 1,759bps to -168.83% in 2022, then surged by 5,352bps to -115.30% in 2023, then skyrocketed by 4,599bps to -69.31% in 2024, then tumbled by 1,058bps to -7.88% in 2025.
  • Its EBITDA Margin was -7.88% in Q3 2025, compared to -8.22% in Q2 2025 and -10.20% in Q1 2025.